logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Shandong Gold Mining (01787) will pay an interim dividend of HK$1.15436 per 10 shares on September 7.

date
20:46 03/08/2026
avatar
GMT Eight
Shandong Gold (01787) announced that it will distribute a mid-term dividend of HKD 1.15436 for every 10 shares on September 7, 2026.
Shandong Gold Mining (01787) announced that it will distribute a mid-term dividend of HKD 1.15436 per 10 shares on September 7, 2026.
Related Articles
China Stock
Guizhou Yibai Pharmaceutical (600594.SH): Compound Cantharidin Capsules and others are expected to be selected for centralized procurement.
HK Stock
ALPHAMAB-B(09966): JSKN033 has received approval from CDE to conduct a Phase III clinical study for the treatment of cervical cancer.
China Stock
Hunan Warrant Pharmaceutical (688799.SH): Ferrous Succinate Tablets and others are expected to be selected for national centralized drug procurement.
Guizhou Yibai Pharmaceutical (600594.SH): Compound Cantharidin Capsules and others are expected to be selected for centralized procurement.
China Stock
ALPHAMAB-B(09966): JSKN033 has received approval from CDE to conduct a Phase III clinical study for the treatment of cervical cancer.
HK Stock
Hunan Warrant Pharmaceutical (688799.SH): Ferrous Succinate Tablets and others are expected to be selected for national centralized drug procurement.
China Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.